Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that a presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 24 June 2021 (US ET) as part of OTCQX’s Virtual Life Sciences Investor Forum. The Life Sciences Investor Forum is a leading investor conference that is attended by tens of thousands of investors, primarily US-based retail investors, as well as...
Melbourne, Australia; 21 June 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) advises that its UK retail partner, LloydsPharmacy, has received correspondence from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in relation to specific promotional claims made for VIRALEZE™ antiviral nasal spray. The correspondence relates to promotional claims, including references to...
Further antiviral testing has confirmed SPL7013 (VIRALEZE™ active) has potent virucidal activity against the Alpha (UK), Beta (South Africa) and Gamma (Japan/Brazil) variant strains of SARS-CoV-2 coronavirus
... VIRALEZE™ has been registered for sale nationally in India ... VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimer sodium (SPL7013) which is virucidal, irreversibly inactivating >99.9% of SARS-CoV-2 (the virus that causes COVID-19) within one minute ... The active in VIRALEZE™ is also highly active against multiple strains and...
"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.
News18 reports on Starpharma's latest VIRALEZETM announcement: "New data released today shows that Australia’s Viraleze anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus." Read the full article here.
Markets Insider features Starpharma's latest announcement, ..."The results hold significant promise for Viraleze™ – developed by Melbourne-based biopharmaceutical company Starpharma (ASX: SPL) – in the fight against new and emerging variants of SARS-CoV-2, as several countries begin their long-awaited opening of international borders..." Read the full article here.
"New data released today shows that Australia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus," as reported by the New Delhi Times. Read the full article here.